Profile data is unavailable for this security.
About the company
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
- Revenue in USD (TTM)0.00
- Net income in USD-106.47m
- Incorporated2009
- Employees106.00
- LocationAura Biosciences Inc80 Guest StreetBOSTON 01235United StatesUSA
- Phone+1 (617) 500-8864
- Fax+1 (302) 655-5049
- Websitehttps://aurabiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immix Biopharma Inc | 0.00 | -23.56m | 310.31m | 18.00 | -- | 23.78 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 312.52m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 314.07m | 56.00 | -- | 0.9946 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 317.06m | 17.00 | -- | 1.79 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 323.00m | 95.00 | -- | 2.40 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 324.67m | 299.00 | -- | 1.03 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 335.60m | 28.00 | -- | 1.90 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 340.38m | 106.00 | -- | 2.15 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Anavex Life Sciences Corp | 0.00 | -46.38m | 340.42m | 34.00 | -- | 3.48 | -- | -- | -0.5439 | -0.5439 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -38.75 | -33.08 | -43.11 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 349.00m | 4.00 | -- | 159.03 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 360.90m | 16.00 | -- | 4.29 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 366.31m | 226.00 | -- | 1.15 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 367.29m | 64.00 | -- | 3.06 | -- | 23.33 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 368.34m | 305.00 | -- | 0.595 | -- | 13.00 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 374.17m | 123.00 | -- | 47.24 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Aura Biosciences Inc's reporting currency: US Dollar USD
54.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 30 Sep 2025 | 6.92m | 11.14% |
| Adage Capital Management LPas of 30 Sep 2025 | 4.88m | 7.86% |
| Long Focus Capital Management LLCas of 30 Sep 2025 | 4.62m | 7.44% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 4.37m | 7.04% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.06m | 4.93% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.55m | 4.11% |
| Franklin Advisers, Inc.as of 30 Sep 2025 | 2.20m | 3.54% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 2.12m | 3.41% |
| Lundbeckfond Invest A/Sas of 30 Sep 2024 | 1.75m | 2.82% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.26m | 2.03% |
More ▼
Data from 11 Apr 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
